Aprea Therapeutics Files 8-K
Ticker: APRE · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, corporate-events
Related Tickers: APRE
TL;DR
APRE filed an 8-K on 9/8/25, check for corporate updates.
AI Summary
Aprea Therapeutics, Inc. filed an 8-K on September 8, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has its principal executive offices at 3805 Old Easton Road, Doylestown, PA. The filing does not detail specific transactions or financial figures but serves as a notification of corporate events.
Why It Matters
This filing indicates that Aprea Therapeutics is making a regulatory disclosure to the SEC, which could contain updates on corporate actions or financial reporting relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks without further details on its content.
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Registrant
- September 8, 2025 (date) — Date of Report
- 3805 Old Easton Road Doylestown , PA 18902 (address) — Principal executive offices
- 001-39069 (company_id) — Commission File Number
FAQ
What specific events are being reported in this 8-K filing by Aprea Therapeutics?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as the items being reported, but the specific details of these events are not provided in the provided text.
When was this 8-K filing submitted by Aprea Therapeutics?
The filing was submitted on September 8, 2025.
What is Aprea Therapeutics' primary business sector?
Aprea Therapeutics is in the 'PHARMACEUTICAL PREPARATIONS' sector, with SIC code 2834.
Where are Aprea Therapeutics' principal executive offices located?
The principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.
What is the Commission File Number for Aprea Therapeutics?
The Commission File Number for Aprea Therapeutics is 001-39069.
Filing Stats: 422 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-09-08 07:45:20
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
Filing Documents
- apre-20250908x8k.htm (8-K) — 38KB
- apre-20250908xex99d1.htm (EX-99.1) — 34KB
- apre-20250908xex99d1g001.jpg (GRAPHIC) — 130KB
- apre-20250908xex99d1g002.jpg (GRAPHIC) — 253KB
- apre-20250908xex99d1g003.jpg (GRAPHIC) — 95KB
- apre-20250908xex99d1g004.jpg (GRAPHIC) — 113KB
- apre-20250908xex99d1g005.jpg (GRAPHIC) — 166KB
- apre-20250908xex99d1g006.jpg (GRAPHIC) — 87KB
- apre-20250908xex99d1g007.jpg (GRAPHIC) — 168KB
- apre-20250908xex99d1g008.jpg (GRAPHIC) — 111KB
- apre-20250908xex99d1g009.jpg (GRAPHIC) — 74KB
- apre-20250908xex99d1g010.jpg (GRAPHIC) — 168KB
- apre-20250908xex99d1g011.jpg (GRAPHIC) — 175KB
- apre-20250908xex99d1g012.jpg (GRAPHIC) — 138KB
- apre-20250908xex99d1g013.jpg (GRAPHIC) — 87KB
- apre-20250908xex99d1g014.jpg (GRAPHIC) — 130KB
- apre-20250908xex99d1g015.jpg (GRAPHIC) — 88KB
- apre-20250908xex99d1g016.jpg (GRAPHIC) — 158KB
- apre-20250908xex99d1g017.jpg (GRAPHIC) — 138KB
- apre-20250908xex99d1g018.jpg (GRAPHIC) — 96KB
- apre-20250908xex99d1g019.jpg (GRAPHIC) — 163KB
- apre-20250908xex99d1g020.jpg (GRAPHIC) — 193KB
- apre-20250908xex99d1g021.jpg (GRAPHIC) — 146KB
- 0001558370-25-011909.txt ( ) — 4135KB
- apre-20250908.xsd (EX-101.SCH) — 4KB
- apre-20250908_def.xml (EX-101.DEF) — 3KB
- apre-20250908_lab.xml (EX-101.LAB) — 16KB
- apre-20250908_pre.xml (EX-101.PRE) — 11KB
- apre-20250908x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 8, 2025, Aprea Therapeutics, Inc. updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.1 hereto and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Corporate Presentation (September 2025). 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: September 8, 2025 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer